ArticleNanoscale2018
Delivery of thrombolytic therapy using rod-shaped plant viral nanoparticles decreases the risk of hemorrhage.
Article in Nanoscale, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 39 citations in OpenAlex.
- Novel Bioconjugate Materials: Synthesis, Characterization and Medical Applications.Advanced healthcare materials · 2025Review
- Advancements in nanomedicine for modulating ischemic cardiomyopathy therapy.Materials today. Bio · 2025Review
- Nanoparticles for Thrombolytic Therapy in Ischemic Stroke: A Systematic Review and Meta-Analysis of Preclinical Studies.Pharmaceutics · 2025Review
- Role of Nanotechnology in Ischemic Stroke: Advancements in Targeted Therapies and Diagnostics for Enhanced Clinical Outcomes.Journal of functional biomaterials · 2025Review
- Virus-like particle encapsulation of functional proteins: advances and applications.Theranostics · 2024Review
- Biomaterials-Enabled Antithrombotics: Recent Advances and Emerging Strategies.Molecular pharmaceutics · 2022Review
- Heparin-Peptide Nanogranules for Thrombosis-Actuated Anticoagulation.Small (Weinheim an der Bergstrasse, Germany) · 2022Article
- The viral capsid as novel nanomaterials for drug delivery.Future science OA · 2021Review
- Review
- Designing S100A9-Targeted Plant Virus Nanoparticles to Target Deep Vein Thrombosis.Biomacromolecules · 2021Article
- The pharmacology of plant virus nanoparticles.Virology · 2021Review
- Advances in Nanomaterials for Injured Heart Repair.Frontiers in bioengineering and biotechnology · 2021Review
- Plant Viruses and Bacteriophage-Based Reagents for Diagnosis and Therapy.Annual review of virology · 2020Review
- Viral nanoparticles for drug delivery, imaging, immunotherapy, and theranostic applications.Advanced drug delivery reviews · 2020Review
- Plant Molecular Farming as a Strategy Against COVID-19 - The Italian Perspective.Frontiers in plant science · 2020Article
- Biomimetic nanoparticle technology for cardiovascular disease detection and treatment.Nanoscale horizons · 2020Review
- Development of improved dual-diazonium reagents for faster crosslinking of tobacco mosaic virus to form hydrogels.RSC advances · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 3 countries.
Funding
Abstract
Cardiovascular thrombotic disease is an underlying cause of stroke, myocardial infarction and pulmonary embolism - some of the leading causes of death worldwide. Reperfusion therapy with anticoagulant, antiplatelet, and fibrinolytic agents has significantly reduced early mortality and morbidity from acute myocardial infarction and stroke. Nevertheless, bleeding side effects (e.g., intracranial hemorrhage) associated with the anti-thrombotic therapy can offset its benefits and limit its applicability to strictly defined short therapeutic windows. We have previously shown that elongated plant virus based nanoparticles can target cardiovascular thrombi and exhibited their utility for the delivery of streptokinase in an ex vivo model of thrombosis. Herein, we build upon our previous findings and demonstrate plant viral delivery of the current standard-of-care tissue plasminogen activator (tPA). Studies on a pre-clinical mouse model of arterial thrombosis indicate that while the therapeutic efficacy of free tPA and tPA-conjugated TMV are similar, the safety profile of the tPA-TMV formulation is improved, i.e. administration of the latter has less impact on hemostasis as demonstrated by decreased bleeding time. Thus, our data suggest that TMV-based delivery of thrombolytic therapies could be a promising and safer alternative to reperfusion therapy with the tPA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.